<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784964</url>
  </required_header>
  <id_info>
    <org_study_id>CT21</org_study_id>
    <nct_id>NCT02784964</nct_id>
  </id_info>
  <brief_title>Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis</brief_title>
  <official_title>A Phase I/II Study to Evaluate the Safety and Efficacy of the Allogeneic Injection of Expanded Adipose-derived Stem Cells to Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UnicoCell Biomed CO. LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>A2 Healthcare Taiwan Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UnicoCell Biomed CO. LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To assess the safety of allogeneic injection of expanded ADSCs to patients with knee
           osteoarthritis

        2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with knee
           osteoarthritis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline to post-treatment visit of WOMAC pain score at week 24 after treatment</measure>
    <time_frame>Weeks 0, 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to post-treatment visits of Visual Analogue Scale (VAS) to measure Pain Levels</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to post-treatment visits of scores of sections in Knee Society Clinical Rating System (KSCRS) Score</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically abnormal MRI examination results and/or adverse events that are related to treatment</measure>
    <time_frame>Weeks 0, 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to post-treatment visits of total score, and sub-scores of all sections in WOMAC</measure>
    <time_frame>Weeks 0, 2, 4, 12, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total acetaminophen consumption amount during the first 24 weeks and the whole study period</measure>
    <time_frame>Week 0, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total non-steroidal anti-inflammatory drug (NSAID) consumption amount during the first 24 weeks and the whole study period</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subject first time consumes acetaminophen</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subject first time consumes non-steroidal anti-inflammatory drug (NSAID)</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically abnormal laboratory values and/or adverse events that are related to treatment</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically abnormal vital signs and/or adverse events that are related to treatment</measure>
    <time_frame>Weeks 0, 2, 4, 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Elixcyte 8mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADSC 6.4*10^7 cells, allogeneic injection, one time injection on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hya Joint Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc., one time injection on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elixcyte 4mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADSC 3.2*10^7 cells, allogeneic injection, one time injection on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elixcyte 2mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADSC 1.6*10^7 cells, allogeneic injection, one time injection on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Elixcyte 8 ml</intervention_name>
    <description>ADSC 6.4*10^7 cells, allogeneic injection</description>
    <arm_group_label>Elixcyte 8mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hya Joint Plus</intervention_name>
    <description>Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.</description>
    <arm_group_label>Hya Joint Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Elixcyte 4 ml</intervention_name>
    <description>ADSC 3.2*10^7 cells, allogeneic injection</description>
    <arm_group_label>Elixcyte 4mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Elixcyte 2 ml</intervention_name>
    <description>ADSC 1.6*10^7 cells, allogeneic injection</description>
    <arm_group_label>Elixcyte 2mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 40-80 years (inclusive)

          2. Kellgren-Lawrence grading I-III, as determined by American College of Rheumatology
             (ACR) criteria for osteoarthritis of the knee

          3. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score of
             7-17 in the study knee even if treated with chronic doses of non steroidal
             anti-inflammatory drugs

          4. Having provided informed consent

        Exclusion Criteria:

          1. With previous surgery of articular fracture, ligament reconstruction, meniscal
             reconstruction, and knee arthroplasty on the target knee joint

          2. With previous intra-articular intervention on the target knee joint within past 3
             months (e.g. steroid, anaesthetic, sodium hyaluronate)

          3. Known or suspected infection of the target knee joint

          4. Ascertained hypersensitivity to any component used in the study

          5. Administered with systemic anti-inflammatory drugs (e.g. non-steroidal
             anti-inflammatory drug or steroid ) or topical anti-inflammatory drugs on target knee
             within 7 days prior to administration in the study

          6. With serious prior or ongoing medical conditions (e.g. concomitant illness such as
             cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g.
             Child-Pugh Class C), psychiatric condition, alcoholism, drug abuse), medical history,
             physical findings, , or laboratory abnormality that in the investigators' opinion
             could interfere with the results of the trial or adversely affect the safety of the
             patient

          7. With any evidence of malignant disease with life expectancy of less than 1 year

          8. Pregnant or lactating women or planning to be pregnant during the study period

          9. With body mass index (BMI) greater or equal to 35 kg/m2

         10. With joint diseases except knee osteoarthritis considered by investigator not eligible
             to enter the study

         11. With known history of human immunodeficiency virus (HIV) infection.

         12. Judged to be not applicable to this study by investigator such as difficulty of
             follow-up observation

         13. With any other serious diseases/medical history considered by the investigator not in
             the condition to enter the trial

         14. Having participated other investigational study within 4 weeks of entering this study

         15. With known history of claustrophobia

         16. Having any existing active/inactive implanted medical devices, such as cardiac
             pacemaker, cochlear, intracranial vascular clips or neurostimulator, etc...

         17. Having any existing metallic intraocular foreign body
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Han Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Fong Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chia-Wen Chien, Ph.D.</last_name>
    <phone>886-2-2791-1826</phone>
    <phone_ext>134</phone_ext>
    <email>baba@unicocell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Linkou</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Han Chang, MD</last_name>
      <phone>886-3-319-6200</phone>
      <email>yhchang@cgmh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

